MARKSANS PHARMA LTD. - 524404 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements), 201505-07-2023
05-07-2023
MARKSANS PHARMA LTD. - 524404 - Closure of Trading Window
Trading Window for the designated persons and/or their immediate relatives will remain closed from Saturday, 1st July, 2023 till 48 hours after the declaration of unaudited financial results for the quarter ended 30th June, 2023. The date of declaration of financial results will be intimated separately in due course of time.30-06-2023
MARKSANS PHARMA LTD. - 524404 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201520-06-2023
MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Transcript of Q4 FY23 Earnings Conference Call held on May 31, 202307-06-2023
MARKSANS PHARMA LTD. - 524404 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201506-06-2023
MARKSANS PHARMA LTD. - 524404 - Announcement Under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Pursuant to Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, the audio recording of the aforesaid Financial Results Conference Call is hosted on the website of the Company under the following link: http://marksanspharma.com/investors-meet.html31-05-2023
MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclosed herewith copies of audited financial results of the Company for the quarter and year ended March 31, 2023 published on May 31, 2023 in the Business Standard (English) and Lakshadeep (Marathi) newspapers.31-05-2023
Q4FY23 Quarterly & FY23 Annual Result Announced for Marksans Pharma Ltd.
Pharmaceuticals company Marksans Pharma announced Q4FY23 & FY23 results: Q4FY23: Operating revenue was Rs 486.0 crore, up by +16.3% YoY driven by market share gains in the existing products and markets US business grew by +12.8% YoY UK and Europe grew by +33.1% YoY Gross profit was Rs 242.1 crore, up by +17.3% YoY with a Gross margin of 49.8% EBITDA was Rs 109.5 crore, grew by 72.1% with an EBITDA margin of 22.5% EPS grew by 185.5% YoY to Rs 2.0 FY23: Operating revenue at Rs 1,852.1 crore, increased by 24.2% YoY Gross profit at Rs 930.8 crore, grew by +20.3% YoY with a Gross margin at 50.3% EBITDA at Rs 339.3 crore, increased 31.1% YoY with EBITDA margin at 18.3% Cash balance stood at a healthy Rs 715.0 crore as of 31st March 2023 Free Cash Flow was Rs 183.8 crore Mark Saldanha, Managing Director of the company said, "Our consistent growth trend continues in the quarter, driven by gains in existing store brands, products, and markets, as well as normalization of freight expenses. We have completed the acquisition of Teva Pharma manufacturing unit in Goa which will enable us to accelerate the growth of our business and strengthen our position as a leading low-cost manufacturer. We have exceeded our FY23 guidance of Rs 1,800 crore. This milestone is our testament to our commitment to delivering value creation for our stakeholders. We aim to continue our success in the coming year, with a focus on extending our footprint in the multi-billion-dollar OTC opportunities, focusing on margin improvement, and strengthening our balance sheet”. Result PDF30-05-2023
MARKSANS PHARMA LTD. - 524404 - Disclosure Of Related Party Transactions Under Regulation 23(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Pursuant to Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith disclosure of related party transactions for the half year ended 31st March, 2023.30-05-2023
MARKSANS PHARMA LTD. - 524404 - Statement On Deviation Or Variation Of Funds Raised Through Preferential Issue Of Convertible Warrants.
Statement on Deviation or Variation of funds raised through Preferential Issue of Convertible Warrants.30-05-2023